Insulins - Halozyme

Drug Profile

Insulins - Halozyme

Alternative Names: Analog insulin-PH20; Aspart-PH20; Hyaluronidase-insulin; Insulin-hyaluronidase; Insulin-PH20; Lispro-PH20; Recombinant human hyaluronidase-insulin; rHuPH20/insulin; Ultrafast Insulin

Latest Information Update: 07 Aug 2015

Price : $50

At a glance

  • Originator Halozyme Therapeutics
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Hyaluronidase stimulants; Ornithine decarboxylase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 07 Aug 2015 Phase-II development for Type 1 diabetes mellitus and Type 2 diabetes mellitus is ongoing in USA
  • 31 Mar 2015 Insulins - Halozyme is available for licensing as of 31 Mar 2015. http://www.halozyme.com
  • 24 Jul 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top